Industrial partners
In order to realize the ambition of RegMed XB to bring solutions to the patients on a large scale the RM products we develop will have to be commercialized. This will ensure large-scale production and efficient production methods to reduce costs. Furthermore, the expertise in the RegMed XB ecosystem can also boost the development of new and existing products from the emerging RM companies. All in all, it is a perfect match to partner up with companies to access their expertise to design scalable and feasible products and together scout for opportunities to valorize new opportunities in the pipeline of the companies or the academic partners. Currently, we have strong partnerships with the following entities.
Access2Bone
Access2Bone is a start-up in the orthopaedic market of bone void fillers. Worldwide the number of bone grafting procedures performed in an ever more geriatric population is growing rapidly. For a growing group of geriatric patients with a compromised bone regeneration metabolism Access2Bone is to create the best bone void filling solutions surgeons need to help these patients best. Access2Bone envisions to lead the high-end segment of bone void fillers by creating highly osteo inductive products that are safe by design and disruptively efficient. Access2Bone’s products are based on naturally derived growth factors. Access2Bone is aiding the Osteoarthritis Moonshot with coating implants that being developed by the Moonshot team with A2B’s growth factors to stimulate fusion between the patient’s bone and the implants being developed.
CiMaas B.V.
CiMaas is able to culture large quantities of NK cells from peripheral blood of healthy donors that are used for the analyses.
CiMaas is facilitating within RegMed XB's research the analysis of a possible immune response to regmedXB products. Specifically, the immune response by natural killer (NK) cells.
Coagulation Profile
Coagulation Profile is an established research partner and service provider for pharmaceutical and biotech companies around the globe, renowned for its portfolio of high-quality standard and custom-made coagulation marker assays available for preclinical and clinical research under GLP and GCP conditions. Targets include coagulation markers related to the vessel wall (such as ucMGP and PIVKA-II) and blood (ranging from standard PT and aPTT assays to custom-made antigen and enzyme activity assays), as well as flow assessments including the Maastricht Flow Chamber and thromboelastography.
Coagulation Profile specializes in the TGA, a highly sensitive method that captures both pro- and anticoagulant mechanisms in the same analysis, thus providing a complete picture of a patient's risk of bleeding or developing thrombosis at a given point in time.
GenDx
GenDx is a global leader in molecular diagnostics for matching stem cell transplant patients with donors, and monitoring success after transplantation. We combine our in-house developed software and reagents for Chimerism monitoring and high-resolution HLA typing by Next Generation Sequencing with excellent customer support and education. We work closely with our partners and clients by sharing knowledge and train lab professionals to advance the field of transplant typing and monitoring. With a highly educated and motivated team of about 100 people and 40 distributors, we contribute to the quality of life of transplant patients.
NecstGen
NecstGen is a mission-driven CDMO owned by Leiden University Medical Center (LUMC). This large-scale investment to support academia and industry was undertaken to address the barriers to entry for the creation of next-generation therapeutics, including:
- Investment: The high cost of capital equipment, facilities, research, and development.
- Limited capacity: Market availability of development and manufacturing slots.
- Know-how: Knowledge, expertise, and talent acquisition.
- Intellectual property: Complex ownership and control of the technologies required to realise new therapies successfully.
Quality Assistance
Quality Assistance is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.
The company holds a unique place on the market with all of its laboratories on one site, 230 highly-qualified professionals and 40 years’ expertise at the forefront of analytical sciences.
They assist their clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using their state-of-the-art, product-dedicated expertise in analytical sciences. For each customer and each project, they design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.
Scinus Cell Expansion Netherlands
Scinus Cell Expansion develops and distributes bioreactor technology for stem cell cultivation. The system enables clinical scale cell cultivation in a controlled environment, which we feel is a cost effective alternative to 2D cell growth in tissue culture flasks or cell stacks. The system contains a single use bioreactor bag that can be used to cultivate stem cells (e.g. human mesenchymal stromal cells) to clinically relevant numbers of cells. Adherent cells are grown on microcarriers in a single use, expandable bioreactor bag with continuous pH and dissolved oxygen control and biomass monitoring, which provides an optimized environment for growing cells. In addition to that, Scinus is also working on expansion of suspension cells (like T-Cells, NK Cells). Therefore we have a dedicated single use suspension bioreactor bag. The closed system minimizes the risk of contamination. For an illustrative animation, please check our website.
Xeltis
A clinical-stage medical device company, Xeltis developed the world’s first polymer-based technology platform to enable natural restoration of heart valves and blood vessels within the body.
The technology uses the patient’s own natural healing system to develop a new living functional vascular graft or heart valve. Xeltis devices are made of supramolecular polymers (a Nobel prize awarded discovery). They are manufactured with electrospinning methods to create small diameter vascular grafts and heart valve implants with a unique micro-porous architecture.